Favorable predictors for survival in advanced ALK-positive non-small cell lung cancer patients beyond crizotinib resistance.

Hai-Yan XuGuangjian YangLu YangYaning YangDi MaJunling LiXuezhi HaoPuyuan XingYan Wang

Published in: Thoracic cancer (2019)

Long PFS with crizotinib (≥10.4 months), intracranial progression, and use of next-generation ALK inhibitors might be favorable predictors for OS in advanced ALK-positive NSCLC patients.

Keyphrases

advanced non small cell lung cancer
end stage renal disease
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
small cell lung cancer
patient reported
tyrosine kinase